Amylin investors are bracing for new competition in the diabetes market from two Big Pharma powers: Merck and Novartis. But Amylin’s president is not worried. In fact — he’s breaking out the welcome mat.
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/